683 Capital Management, LLC Altimmune, Inc. Transaction History

683 Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.19 - $16.83 $13,315 - $53,485	-3,178 Reduced 18.5%	14,000 $59,000
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $150,135 - $282,578	17,178 New	17,178 $282,000
Q1 2021 May 17, 2021	SELL	$12.71 - $24.31 $415,337 - $794,402	-32,678 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $256,195 - $464,681	32,678 New	32,678 $369,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.